$XBI $138.06 -1.17%
Covid Updates
$VRNA -5.56% Last week ensifentrine reported was well tolerated in patients hospitalized with COVID-19. source
Pipeline Updates
$ELOX -0.92% Adding new study arm to ongoing Phase 2 trial of ELX-02 to treat CF. source
$IDRA -5.6% Continuing to explore potential for tilsotolimod after disappointing ORR results in advanced melanoma. source
$XERS -4.0% MHRA approved Ogluo injection to treat sever hypoglycaemia. source
$PHAT -0.2% Pivotal Phase 3 trial of vonoprazan met primary and secondary endpoints. source
$PLX -9.9% Inspection of facility required (reported on 4/28) before BLA approval. source
$TRIL +6.5% Doses first patient in Phase 1b study on 4/28. source
$GRTX +22.8% Interim data analysis of Phase 1/2 trial reported; expect final results during second half of year. source
$SELB -19.0% Submission of IND for MMA-101 to be delayed due to manufacturing issue. source
$ADVM -62.3% Suspected Unexpected Serious Adverse Reaction of hypotony reported in INFINITY trial. source
$GALT -16.9% Presented at NASH congress today and reviewed scientific and clinical activities in NASH cirrhosis. source
$MORF -2.5% Received acceptance to present full MORF-057 Phase 1 data set at the ECCO’21 Virtual Congress in July. source
$MGNX +1.0% Will present MGC018 data at ASCO in June 2021. source
$EVLO +1.2% Presented EDP1815 positive Phase 1b data at Atopic Dermatitis meeting. source
$BPMC 1.7% Preparing to launch avapritinib in advanced SM this quarter. source
$AMRN +1.0% VAZKEPA in Europe to be launched in third quarter of 2021. source
$AGIO +0.7% Phase 3 study data to be presented at EHA 2021. source
$ARDX -6.1% PDUFA date for Tenapanor extended by three months to July 29, 2021. source
$APLS +6.5% Application for pegcetacoplan under review with PDUFA date of 5/14/2021; Phase 3 data from PNH trial expected in second quarter 2021. source
$IBRX -7.2% Launched Phase 2 trial of Anktiva to treat acute HIV infection. source
$JAGX -8.4% Poster presentation accepted for ASCO 2021 to present data on Mytesi. source
$ANVS -2.5% Plan to study ANVS401 to normalize brain development in down syndrome. source
$CARA -45.4% Phase 2 KARE trial of KORSUVA reports topline results. source
$LTRN -0.6% RADR AI platform is improving drug discovery and development; exceeded 4.6 billion datapoints. source
$LABP -2.6% First patient dosed in NX-13 Phase 1b trial. source
$APTX -6.0% Phase 2 positive data for NYX-783 reported at Society of Biological Psychiatry Annual meeting. source
$AERI -1.5% Enrollment in AR-15512 COMET-1 Phase 2b trial completed. source
Finance Updates
$INRLF +13.1% Launhces proposed global offering. source
$OCUL +22.7% Presenting financials on 5/6; presenting clinical programs at ARVO on 5/2. source
$ALDX -10.2% Announced pricing of 10M shares of common stock on 4/28. Will report financials on 5/6. source
$MIRM -4.7% Entered into exclusive licensing agreement with CANbridge Pharmaceuticals. source
$CAPR +14.9% Signed licensing agreement with Johns Hopkins University to expand exosome platform technology. source
$XLRN -1.2% Expect to report $112M in net sales of REBLOZYL in first quarter of 2021. source